PAMU
PTLA

Pictet Asset Management (UK)’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Pictet Asset Management (UK)’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-306,764
Closed -$2.19M – 1225
2020
Q1 		$2.19M Sell
306,764
-557,692
-65% -$6.96M ﹤0.01% 837
2019
Q4 		$20.6M Buy
864,456
+737,656
+582% +$20.3M 0.04% 436
2019
Q3 		$3.4M Buy
+126,800
New +$3.56M 0.01% 786
2019
Q2 		– Sell
-97,642
Closed -$3.39M – 1062
2019
Q1 		$3.39M Buy
97,642
+31,100
+47% +$897K 0.01% 779
2018
Q4 		$1.3K Sell
66,542
-197,030
-75% -$4.05M ﹤0.01% 872
2018
Q3 		$7.02M Sell
263,572
-318,854
-55% -$10.4M 0.01% 645
2018
Q2 		$22M Sell
582,426
-16,105
-3% -$616K 0.05% 374
2018
Q1 		$19.5M Sell
598,531
-112,203
-16% -$4.92M 0.05% 385
2017
Q4 		$34.6M Buy
710,734
+232,044
+48% +$11.7M 0.09% 278
2017
Q3 		$25.9M Sell
478,690
-43,547
-8% -$2.56M 0.07% 320
2017
Q2 		$19.2M Sell
522,237
-108,621
-17% -$4.35M 0.06% 355
2017
Q1 		$24.7M Sell
630,858
-43,894
-7% -$1.4M 0.08% 314
2016
Q4 		$15.1M Buy
674,752
+88,597
+15% +$1.73M 0.06% 369
2016
Q3 		$13.3M Sell
586,155
-97,486
-14% -$2.29M 0.05% 386
2016
Q2 		$18.8M Buy
683,641
+607,141
+794% +$15M 0.07% 310
2016
Q1 		$2.15M Buy
76,500
+62,000
+428% +$1.97M 0.01% 686
2015
Q4 		$746K Sell
14,500
-96,650
-87% -$4.69M ﹤0.01% 798
2015
Q3 		$4.74M Sell
111,150
-32,600
-23% -$1.57M 0.02% 565
2015
Q2 		$7.11M Buy
143,750
+43,500
+43% +$1.75M 0.03% 497
2015
Q1 		$3.58M Sell
100,250
-62,772
-39% -$2.16M 0.01% 653
2014
Q4 		$4.62M Buy
163,022
+75,272
+86% +$2.09M 0.02% 593
2014
Q3 		$2.22M Buy
87,750
+2,900
+3% +$76.4K 0.01% 717
2014
Q2 		$2.48M Buy
84,850
+22,100
+35% +$535K 0.01% 705
2014
Q1 		$1.63M Buy
62,750
+10,700
+21% +$286K 0.01% 755
2013
Q4 		$1.34M Buy
52,050
+5,300
+11% +$129K 0.01% 769
2013
Q3 		$1.25M Buy
46,750
+13,050
+39% +$311K 0.01% 765
2013
Q2 		$828K Buy
+33,700
New +$670K ﹤0.01% 781

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Pictet Asset Management (UK)'s PTLA Position: Q2 2020 in Review

Pictet Asset Management (UK) sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 306,764 shares — an estimated $2.19M sold.

Pictet Asset Management (UK) first reported a position in PTLA in Q2 2013 and held it in 27 quarters. The position peaked at $34.6M in Q4 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Pictet Asset Management (UK) reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Pictet Asset Management (UK) sold 306,764 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $2.19M.
  • Pictet Asset Management (UK) first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
  • Pictet Asset Management (UK)'s Portola Pharmaceuticals, Inc. position peaked at $34.6M in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2020, filed 13 Aug 2020.